A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer

Completed · Phase 1/Phase 2

Conditions studied: Hormone Receptor Positive Breast Carcinoma, HER2-negative Breast Cancer

In brief

This clinical trial is a Phase I dose escalation and dose expansion and Phase II monotherapy open-label, first-in-human, multicenter study of OP-1250 in adult subjects with advanced and/or metastatic hormone receptor (HR)-positive, her2-negative breast cancer.

Key facts

Study ID
NCT04505826
Run by
Olema Pharmaceuticals, Inc.
People needed
153
Starts
2020-08-13
Expected to finish
2024-07-30
Last updated by the study team
2026-05-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.